MedTrace Logo

Trifecta-Heart cfDNA-MMDx Study

NCT04707872 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-03-18

No results posted yet for this study

Summary

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

Conditions

  • Heart Transplant Rejection

Interventions

DIAGNOSTIC_TEST

MMDx diagnostic test

Microarray test of gene expression in heart biopsies

DIAGNOSTIC_TEST

Prospera

Donor derived cell-free DNA in patient blood

DIAGNOSTIC_TEST

HLA antibody

Centralized measurement of HLA antibodies in patient blood

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY

  • One Lambda

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Philip F Halloran, MD PhD · Alberta Transplant Applied Genomics Center, University of Alberta

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-12-31
Completion
2027-07-31

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04707872 on ClinicalTrials.gov